MaartenTaal University of NottinghamUnited Kingdom

MaartenTaal
Maarten Taal MBChB, MMed, MD, FCP(SA), FRCP Maarten graduated from the University of Cape Town Medical School, South Africa, in 1987. After completing his post-graduate training in internal medicine and nephrology at Groote Schuur Hospital, Cape Town, he joined the Laboratory of Kidney and Electrolyte Physiology at Brigham and Women’s Hospital, Boston, USA under the directorship of Barry M. Brenner, MD. His research focused on mechanisms underlying the progression of chronic kidney disease (CKD) and earned him a Doctor of Medicine degree. He subsequently moved to the United Kingdom. He was appointed Professor of Medicine at the University on Nottingham in 2014, where he leads the Centre for Kidney Research and Innovation. He is a Past President of the British Renal Society and current Chair of the International Network of CKD Cohorts. He is Editor-in-Chief of “Current Opinion in Nephrology and Hypertension”, Co-Editor for “Brenner and Rector’s The Kidney”, Academic Editor for “PLOS Medicine” and is on the Editorial Board for “American Journal of Kidney Diseases”.
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/e683b49becaa525651250a70d517bcb1.jpg
First Name
Maarten
Last Name
Taal
Institution
Country.
United Kingdom

Thursday, February 6, 2025

Time Session
11:30 a.m.
1:30 p.m.
KenarJhaveri Chair United States
Osmaniahospital Chair India
MitchellRosner Chair Univeristy of Virginia HealthUnited States
  • Clinical Trials Overview: Focus on GLP1a, MRA, and SGLT2
    MaartenTaal Speaker University of NottinghamUnited Kingdom
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
  • Q and A
Neelkamal Hall 305